Table 1.

Demographics of nasal Foralumab dose cohorts (10μg, 50μg, 250μg) and placebo group.

	Placebo	Foralumab (10μg)	Foralumab (50μg)	Foralumab (250μg)	Foralumab-all doses
N	9	6	6	6	18
Male	6 (66.7%)	4 (66.7%)	3 (50%)	1 (16.7%)	8 (44.4%)
Female	3 (33.3%)	2 (33.3%)	3 (50%)	5 (83.3%)	10 (55.6%)
Mean age +/-SD (range) in years	38.0+/- 16.6 (22-65)	35.8+/-15.5 (23-60)	24.3+/-3.4 (19-29)	29.5+/-11.0 (21-51)	29.9+/- 11.5 (19-60)
Race
White	6 (66.7%)	3 (50%)	2 (33.3%)	1 (16.7%)	6 (33.3%)
Black or African American	2 (22.2%)	0 (0%)	0 (0%)	1 (16.7%)	1 (5.6%)
Asian	1 (11.1%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	5 (27.8%)
American Indian or Alaska Native	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Native Hawaiian or other Pacific	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Other or Unknown ethinicity	0 (0%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	6 (33.3%)
Hispanic or Latino	1 (11.1%)	1 (16.7%)	2 (33.3%)	1 (16.7%)	4 (22.2%)
Non-hispanic or Latino	8 (88.9%)	3 (50%)	4 (66.7%)	5 (83.3%)	12 (66.7%)
Unknown or not reported	0 (0%)	2 (33.3%)	0 (0%)	0 (0%)	2 (11.1%)